Physician profile
John J Gallagher
NPI 1215976899
$878.51
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $155 · 2021: $17.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $254.90 | 2019 | |
| Amgen INC. | $217.59 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $122.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.62 | 2019-2021 | |
| Amarin Pharma, INC. | $87.99 | 2020 | |
| Novartis Pharmaceuticals Corporation | $33.54 | 2019 | |
| Glaxosmithkline, LLC. | $27.96 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $13.30 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.